CPX-351
Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 38 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Chemotherapy
- Trial Type
- Treatment
- Last Update
- 10 months ago
- SparkCures ID
- 1528
- NCT Identifier
- NCT03896269
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.